ALPMY
Astellas Pharma Inc.
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
15.04
▲ 0.08 (0.53%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
14.98
Prev close
14.96
Day high
15.08
Day low
14.98
Volume
29.43K
Market cap
$26.97B
P/E (TTM)
14.60
52W range
10.03 – 17.35
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+2.17%
+3.5%
1M
+14.90%
+11.2%
3M
+4.23%
+1.1%
6M
-5.59%
-16.7%
YTD
+13.17%
+0.9%
1Y
+30.90%
+10.9%
3Y
-1.05%
-75.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$26.97B
Enterprise value$373.90B
Revenue (TTM)$2.27T
Gross profit$1.84T
EBITDA$669.55B
Net income$364.94B
EPS (TTM)$1.03
Free cash flow$383.56B
Total cash$244.70B
Total debt$589.87B
Book value / share$6.82
Shares outstanding1.79B
Float1.79B
Short % of float—
Dividend yield3.29%
Beta (5Y)0.08
Valuation & profitability ratios
Trailing P/E14.60
Forward P/E33.42
PEG ratio—
Price / sales—
Price / book2.21
EV / revenue0.16
EV / EBITDA0.56
Gross margin80.82%
Operating margin28.92%
Profit margin16.05%
Return on equity21.30%
Return on assets8.41%
Debt / equity30.34
Current ratio1.20
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $2.14T | $1.91T | $1.60T | $1.52T | — | +11.9% |
| Operating revenue | $2.14T | $1.91T | $1.60T | $1.52T | — | +11.9% |
| Cost of revenue | $408.43B | $349.21B | $292.49B | $288.35B | — | +17.0% |
| Gross profit | $1.73T | $1.56T | $1.31T | $1.23T | — | +10.7% |
| Research & development | $314.83B | $327.65B | $294.19B | $276.13B | — | -3.9% |
| Selling, general & admin | $860.31B | $843.03B | $740.11B | $630.27B | — | +2.0% |
| Total operating expense | $1.35T | $1.52T | $1.29T | $1.10T | — | -11.3% |
| Operating income | $380.06B | $40.25B | $18.95B | $131.56B | — | +844.3% |
| Net interest income | -$6.05B | -$9.80B | -$550.00M | -$669.00M | — | +38.3% |
| Pre-tax income | $376.59B | $31.24B | $24.97B | $132.36B | — | +1,105.6% |
| Tax provision | $85.01B | -$19.51B | $7.92B | $33.65B | — | +535.7% |
| Net income | $291.54B | $50.75B | $17.05B | $98.71B | — | +474.5% |
| Net income to common | $291.54B | $50.75B | $17.05B | $98.71B | — | +474.5% |
| Basic EPS | 162.77 | — | 9.51 | 54.24 | 67.08 | — |
| Diluted EPS | 162.22 | — | 9.47 | 54.09 | 67.05 | — |
| EBIT | $390.66B | $48.91B | $36.97B | $141.14B | — | +698.7% |
| EBITDA | $585.25B | $248.05B | $194.81B | $246.88B | — | +135.9% |
| Basic shares | 1.79B | 1.79B | 1.79B | 1.82B | — | +0.1% |
| Diluted shares | 1.80B | 1.80B | 1.80B | 1.83B | — | -0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $281.61B | $188.37B | $335.69B | $376.84B | +49.5% |
| Cash & short-term investments | $291.18B | $218.31B | $364.47B | $396.62B | +33.4% |
| Accounts receivable | $746.81B | $632.52B | $534.99B | $427.96B | +18.1% |
| Inventory | $331.01B | $297.26B | $248.74B | $174.39B | +11.4% |
| Total current assets | $1.42T | $1.20T | $1.19T | $1.05T | +18.4% |
| Property, plant & equipment | $358.42B | $328.92B | $293.74B | $286.46B | +9.0% |
| Goodwill & intangibles | $1.44T | $1.54T | $1.87T | $890.91B | -6.6% |
| Total assets | $3.57T | $3.34T | $3.57T | $2.46T | +6.8% |
| Total current liabilities | $1.22T | $1.06T | $1.29T | $726.03B | +14.8% |
| Current debt | $245.95B | $266.53B | $472.28B | $75.00B | -7.7% |
| Long-term debt | $320.00B | $564.89B | $447.74B | $50.00B | -43.4% |
| Total debt | $565.95B | $831.43B | $920.02B | $125.00B | -31.9% |
| Total liabilities | $1.74T | $1.83T | $1.97T | $948.56B | -4.9% |
| Retained earnings | $902.84B | $740.94B | $809.40B | $908.16B | +21.9% |
| Shareholder equity | $1.83T | $1.51T | $1.60T | $1.51T | +20.9% |
| Working capital | $203.52B | $139.74B | -$91.00B | $323.92B | +45.6% |
| Net tangible assets | $390.94B | -$25.67B | -$276.53B | $617.05B | +1,623.2% |
| Shares issued | 1.81B | 1.81B | 1.81B | 1.81B | 0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | $376.59B | $31.24B | $24.97B | $132.36B | +1,105.6% |
| Depreciation & amortisation | $194.59B | $199.13B | $157.84B | $105.74B | -2.3% |
| Change in working capital | -$80.32B | -$166.37B | -$86.52B | -$24.21B | +51.7% |
| Operating cash flow | $560.19B | $194.51B | $172.47B | $327.77B | +188.0% |
| Capital expenditure | -$84.64B | -$57.33B | -$82.50B | -$88.54B | -47.6% |
| Investing cash flow | -$66.72B | -$89.42B | -$845.80B | -$84.50B | +25.4% |
| Share buybacks | -$730.00M | -$6.96B | -$10.73B | -$60.56B | +89.5% |
| Dividends paid | -$136.10B | -$128.99B | -$116.65B | -$100.36B | -5.5% |
| Financing cash flow | -$404.78B | -$261.37B | $614.06B | -$195.62B | -54.9% |
| Free cash flow | $475.54B | $137.18B | $89.98B | $239.23B | +246.7% |
| End cash position | $281.61B | $188.37B | $335.69B | $376.84B | +49.5% |
| Line item | 2026-06-30 | 2025-06-30 | YoY |
|---|---|---|---|
| Basic EPS | 79.15 | 38.22 | +107.1% |
| Diluted EPS | 78.96 | 38.11 | +107.2% |
| Basic shares | 1.79B | 1.79B | +0.1% |
| Diluted shares | 1.80B | 1.80B | +0.0% |
| Line item | 2026-03-31 | 2025-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $281.61B | $188.37B | +49.5% |
| Cash & short-term investments | $291.18B | $218.31B | +33.4% |
| Accounts receivable | $746.81B | $632.52B | +18.1% |
| Inventory | $331.01B | $297.26B | +11.4% |
| Total current assets | $1.42T | $1.20T | +18.4% |
| Property, plant & equipment | $358.42B | $328.92B | +9.0% |
| Goodwill & intangibles | $1.44T | $1.54T | -6.6% |
| Total assets | $3.57T | $3.34T | +6.8% |
| Total current liabilities | $1.22T | $1.06T | +14.8% |
| Current debt | $245.95B | $266.53B | -7.7% |
| Long-term debt | $320.00B | $564.89B | -43.4% |
| Total debt | $565.95B | $831.43B | -31.9% |
| Total liabilities | $1.74T | $1.83T | -4.9% |
| Retained earnings | $902.84B | $740.94B | +21.9% |
| Shareholder equity | $1.83T | $1.51T | +20.9% |
| Working capital | $203.52B | $139.74B | +45.6% |
| Net tangible assets | $390.94B | -$25.67B | +1,623.2% |
| Shares issued | 1.81B | 1.81B | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $579.34B | +10.5% |
| Next quarter | — | — | $616.94B | +8.0% |
| Current year | 1.19 | 1 | $2.32T | +160.7% |
| Next year | 1.10 | 1 | $2.14T | -7.7% |
Analyst targets & ownership
Mean target$17.40
High target$17.40
Low target$17.40
Implied upside15.69%
Analyst count1
ConsensusSTRONG BUY
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions0.02%
Institutions holding11
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
14.77
+1.83% from price
SMA 20
14.38
+4.62% from price
SMA 50
13.73
+9.58% from price
SMA 100
14.30
+5.19% from price
SMA 200
14.20
+5.92% from price
EMA 12
14.65
+2.68% from price
EMA 26
14.29
+5.25% from price
EMA 50
14.09
+6.74% from price
RSI (14)
63.0
Neutral
MACD (12,26,9)
0.36
Hist 0.04
ATR (14)
0.37
2.48% of price
Realised vol 30D
31.0%
Annualised
Bollinger upper
15.41
20, 2σ
Bollinger lower
13.35
20, 2σ
50 / 200 cross
Death
13.73 vs 14.20
Trend bias
Above 200
+5.92%
Risk profile
Beta vs SPY
0.48
Less volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
31.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-22.3%
Peak to trough
Max drawdown 5Y
-50.6%
Peak to trough
ATR 14
0.37
2.48% of price
Beta (reported)
0.08
5Y monthly, from filing
Dividends & splits
Forward rate$0.50 / yr
Forward yield3.29%
5-year avg yield3.60%
Payout ratio47.06%
Ex-dividend dateMar 31, 2026
Next pay dateDec 16, 2021
Last split125:100
Split dateApr 2, 2014
Headlines
New Strong Sell Stocks for August 19th
Zacks · 4d ago
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
PR Newswire · 5d ago
New Strong Sell Stocks for August 6th
Zacks · 17d ago
Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC
Insider Monkey · 38d ago
Pfizer Poised for Mixed Second Quarter, RBC Says
MT Newswires · 43d ago
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Business Wire · 43d ago
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
BioPharma Dive · 60d ago
Sector Update: Healthcare Stocks Advance in Afternoon Trading
MT Newswires · 60d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.